Commentary on "aTTom": long-term effects of continuing adjuvant Tamoxifen to 10 years

被引：7

作者：

Azim, Hamdy A. ^{[1
]}

Saadeldeen, Ahmed ^{[2
]}

机构：

[1] Cairo Univ, Sch Med, Oncol Dept, Cairo, Egypt

[2] Nation Guard Hosp, Med Oncol Dept, Riyadh, Saudi Arabia

来源：

CHINESE CLINICAL ONCOLOGY | 2014年 / 3卷 / 01期

关键词：

D O I：

10.3978/j.issn.2304-3865.2013.12.02

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：3

共 14 条

[1] Comparison of endometrial changes among symptomatic tamoxifen-treated and nontreated premenopausal and postmenopausal breast cancer patients [J].

Cheng, WF ;

Lin, HH ;

Torng, PL ;

Huang, SC .

GYNECOLOGIC ONCOLOGY, 1997, 66 (02) :233-237

[2] Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials [J].

Davies, C. ;

Godwin, J. ;

Gray, R. ;

Clarke, M. ;

Darby, S. ;

McGale, P. ;

Wang, Y. C. ;

Peto, R. ;

Pan, H. C. ;

Cutter, D. ;

Taylor, C. ;

Ingle, J. .

LANCET, 2011, 378 (9793) :771-784

[3] Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial [J].

Davies, Christina ;

Pan, Hongchao ;

Godwin, Jon ;

Gray, Richard ;

Arriagada, Rodrigo ;

Raina, Vinod ;

Abraham, Mirta ;

Medeiros Alencar, Victor Hugo ;

Badran, Atef ;

Bonfill, Xavier ;

Bradbury, Joan ;

Clarke, Michael ;

Collins, Rory ;

Davis, Susan R. ;

Delmestri, Antonella ;

Forbes, John F. ;

Haddad, Peiman ;

Hou, Ming-Feng ;

Inbar, Moshe ;

Khaled, Hussein ;

Kielanowska, Joanna ;

Kwan, Wing-Hong ;

Mathew, Beela S. ;

Mittra, Indraneel ;

Mueller, Bettina ;

Nicolucci, Antonio ;

Peralta, Octavio ;

Pernas, Fany ;

Petruzelka, Lubos ;

Pienkowski, Tadeusz ;

Radhika, Ramachandran ;

Rajan, Balakrishnan ;

Rubach, Maryna T. ;

Tort, Sera ;

Urrutia, Gerard ;

Valentini, Miriam ;

Wang, Yaochen ;

Peto, Richard .

LANCET, 2013, 381 (9869) :805-816

[4] Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors [J].

Fisher, B ;

Dignam, J ;

Bryant, J ;

DeCillis, A ;

Wickerham, DL ;

Wolmark, N ;

Costantino, J ;

Redmond, C ;

Fisher, ER ;

Bowman, DM ;

Deschenes, L ;

Dimitrov, NV ;

Margolese, RG ;

Robidoux, A ;

Shibata, H ;

Terz, J ;

Paterson, AHG ;

Feldman, MI ;

Farrar, W ;

Evans, J ;

Lickley, HL .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (21) :1529-1542

[5] Phase III Clinical Trials That Integrate Treatment and Biomarker Evaluation [J].

Freidlin, Boris ;

Sun, Zhuoxin ;

Gray, Robert ;

Korn, Edward L. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (25) :3158-3161

[6] A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer [J].

Goss, PE ;

Ingle, JN ;

Martino, S ;

Robert, NJ ;

Muss, HB ;

Piccart, MJ ;

Castiglione, M ;

Tu, D ;

Shepherd, LE ;

Pritchard, KI ;

Livingston, RB ;

Davidson, NE ;

Norton, L ;

Perez, EA ;

Abrams, JS ;

Therasse, P ;

Palmer, MJ ;

Pater, JL .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (19) :1793-1802

[7] aTTom (adjuvant Tamoxifen-To offer more?): Randomized trial of 10 versus 5 years of adjuvant tamoxifen among 6,934 women with estrogen receptor-positive (ER+) or ER untested breast cancer-Preliminary results [J].

Gray, R. G. ;

Rea, D. W. ;

Handley, K. ;

Marshall, A. ;

Pritchard, M. G. ;

Perry, P. ;

Earl, H. M. ;

Poole, C. J. ;

Salman, A. ;

Lee, M. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)

[8] Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: Results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a [J].

Jakesz, Raimund ;

Greil, Richard ;

Gnant, Michael ;

Schmid, Marianne ;

Kwasny, Werner ;

Kubista, Ernst ;

Mineritsch, Brigitte ;

Tausch, Christoph ;

Stierer, Michael ;

Hofbauer, Friedrich ;

Renner, Karl ;

Dadak, Christian ;

Ruecklinger, Ernst ;

Samonigg, Hellmut .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (24) :1845-1853

[9] Longer-Term Outcomes of Letrozole Versus Placebo After 5 Years of Tamoxifen in the NCIC CTG MA.17 Trial: Analyses Adjusting for Treatment Crossover [J].

Jin, Huan ;

Tu, Dongsheng ;

Zhao, Naiqing ;

Shepherd, Lois E. ;

Goss, Paul E. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (07) :718-721

[10] Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: Intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 trial [J].

Mamounas, Eleftherios P. ;

Jeong, Jong-Hyeon ;

Wickerham, D. Lawrence ;

Smith, Roy E. ;

Ganz, Patricia A. ;

Land, Stephanie R. ;

Eisen, Andrea ;

Fehrenbacher, Louis ;

Farrar, William B. ;

Atkins, James N. ;

Pajon, Eduardo R. ;

Vogel, Victor G. ;

Kroener, Joan F. ;

Hutchins, Laura F. ;

Robidoux, Andre ;

Hoehn, James L. ;

Ingle, James N. ;

Geyer, Charles E., Jr. ;

Costantino, Joseph P. ;

Wolmark, Norman .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (12) :1965-1971

← 1 2 →